Abstract:FXR agonistic activity screening was conducted based on natural product resources containing 38 structurally diverse sesquiterpenoids isolated from Xylopia vielana. Among them, 34 undescribed sesquiterpenoids with 5 different skeleton types were first characterized by HRESIMS, NMR data, ECD calculations and X-ray crystallographic analysis. High-content screening for FXR agonistic activity of these compounds demonstrated that 13 compounds could activate FXR. Then molecular docking results suggested that hydrogen bonding and hydrophobic interactions might contribute to the main interaction of active compounds with FXR. The preliminary structure-activity relationships (SARs) of those isolates were also discussed. The most potent compound 27 significantly elevated the transcriptional activity of the FXR target gene BSEP promoter (EC50 = 14.26 μM) by a dual-luciferase reporter assay. Western blotting indicated that compound 27 activated the FXR-associated pathway, thereby upregulating SHP and BSEP expression, and downregulating CYP7A1 and NTCP expression. We further revealed that FXR was the target protein of compound 27 through diverse target validation methods, including CETSA, SIP, and DARTS under the intervention of temperature, organic reagents and protease. Pharmacological in vivo experiments showed that compound 27 effectively ameliorated α-naphthyl isothiocyanate (ANIT)-induced cholestasis in mice, as evidenced by the ameliorative histopathology of the liver and the decrease in biochemical markers: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), direct bilirubin (DBIL), and total bile acid (TBA). This work showed a practical strategy for the discovery of new FXR agonists from natural products and provided potential insights for sesquiterpenoids as FXR agonist lead compounds.

Diterpenoid, Steroid, And Triterpenoid Agonists Of Liver X Receptors From Diversified Terrestrial Plants And Marine Sources

Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.

Identification of A Novel Partial Agonist of Liver X Receptor Alpha (lxr Alpha) Via Screening

Discovery of Anti-Hypercholesterolemia Agents Targeting LXRα from Marine Microorganism-Derived Natural Products

Synthesis of liver X receptor agonists from hydeoxycholic acid

Identification of Side Chain Oxidized Sterols As Novel Liver X Receptor Agonists with Therapeutic Potential in the Treatment of Cardiovascular and Neurodegenerative Diseases

Identification of a Novel Partial Agonist of Liver X Receptor Α (lxrα) Via Screening.

Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors

Natural Product-Based Screening Led to the Discovery of a Novel PXR Agonist with Anti-Cholestasis Activity

Lathyrane Diterpenoids As Novel Hpxr Agonists: Isolation, Structural Modification, and Structure-Activity Relationships

Liver X Receptors And Their Agonists: Targeting For Cholesterol Homeostasis And Cardiovascular Diseases

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor

Liver X receptors as potential therapeutic targets for multiple diseases.

In Silico Identification of Small Molecules As Novel LXR Agonists for the Treatment of Cardiovascular Disease and Cancer

Three-Dimensional Pharmacophore Modeling of Liver-X Receptor Agonists

Liver X receptor: a potential target in the treatment of atherosclerosis

Identification of an Oleanane-type Triterpene Hedragonic Acid as a Novel Farnesoid X Receptor Ligand with Liver Protective Effects and Anti-inflammatory Activity.

The discovery of a new potent FXR agonist based on natural product screening

Identify Liver X Receptor Β Modulator Building Blocks by Developing a Fluorescence Polarization-Based Competition Assay.